K. Huang

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

E. Daar, K. Workowski, B. Doehle, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study

M. Vachon, M. Swain, R. Bailey, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

M. Manns, V. de Lédinghen, E. Schiff, 2017, The New England journal of medicine.

Abstract CT012: Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients withBRAFV600mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial

P. Ascierto, H. Gogas, P. Rutkowski, 2020 .

Deferred treatment with a fixed‐dose combination of sofosbuvir‐velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection

T. Asselah, Ching-lung Lai, S. Bourgeois, 2019, Journal of viral hepatitis.

Sofosbuvir/Velpatasvir in Combination with Ribavirin for 24 Weeks is Effective Retreatment for Patients who failed Prior NS5A Containing DAA Regimens: Results of the GS-US-342-1553 Study

C. Stedman, M. Shiffman, E. Gane, 2016 .

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study

E. Daar, K. Workowski, B. Doehle, 2016 .

Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.

M. Manns, N. Terrault, E. Tapper, 2018, Gastroenterology.

SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy

R. Chung, G. Dore, E. Verna, 2017 .

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

M. Manns, E. Schiff, K. Reddy, 2017, The New England journal of medicine.